Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 7.01, 9.01 · 8-K

Integra LifeSciences Holdings Corporation

IARTNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

ITEM 2.02 Results of Operations and Financial Condition. Preliminary Unaudited Results for the Third Quarter On October 2, 2026, Integra LifeSciences Holdings Corporation (the “Company”) announced certain preliminary unaudited results for the third quarter ended September 30, 2026.…

Filed Oct 2, 2026Accepted Oct 2, 2026, 8:20 AM EDTCIK 917520Accession 0000917520-26-000067
Share

Company context

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care.

Current securities

Recent company filings

  1. Regulation FD DisclosureOct 9, 2026
  2. Regulation FD DisclosureSep 8, 2026
  3. SCHEDULE 13G/A - filed by PARADIGM CAPITAL MANAGEMENT INC/NY regarding INTEGRA LIFESCIENCES HOLDINGS CORPAug 13, 2026
  4. SCHEDULE 13G - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding INTEGRA LIFESCIENCES HOLDINGS CORPJul 31, 2026
  5. 10-Q filingJul 29, 2026

Registered securities in this filing

INTEGRA LIFESCIENCES HOLDINGS CORP · 8-K · Filed 2026-10-02

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, Par Value $.01 Per Share

Symbol
IART
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000091752026000067 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
ITEM 2.02 Results of Operations and Financial Condition. Preliminary Unaudited Results for the Third Quarter On October 2, 2026, Integra LifeSciences Holdings Corporation (the “Company”) announced certain preliminary unaudited results for the third quarter ended September 30, 2026. The Company expects its reported revenue to be between $410 million to $412 million, reflecting an estimated $7 million impact of flooding-related supply disruptions on the Company’s manufacturing facility in Cincinnati, Ohio (the “Cincinnati facility”). The Company expects its adjusted earnings per diluted share for the third quarter to be between $0.55 to $0.59. In addition, the Company expects operating cashflow to be greater than $85 million in the third quarter. The preliminary financial information set forth above is unaudited and based on currently available information. It remains subject to completion of the Company’s financial closing procedures, and is not a comprehensive statement of the Company’s financial results for the period. This information does not present all information necessary for a complete understanding of the Company’s results of operations for the period and has not been reviewed by the Company’s independent registered public accounting firm.
Item 7.01Item 7.01 - Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure. On October 2, 2026, the Company issued a press release that announced certain preliminary unaudited results for the third quarter ended September 30, 2026 and provided an update on the Company’s Cincinnati facility. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex991_q3pressreleasepreann.htm

Integra LifeSciences Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance PRINCETON, N.J., October 2, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance. “Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full-year outlook.” Mr. Essig continued, “While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Importantly, we remain encouraged by the progress we are making across the broader b…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.